Surgicure Technologies is a biotechnology start-up focused on developing innovative medical instruments designed to enhance safety and efficiency during surgical procedures and recovery. Founded in 2018 by Irena Volkov and headquartered in Cambridge, Massachusetts, the company specializes in airway management solutions for both civilian and military applications. Surgicure's flagship product secures medical tubes placed within a patient's mouth, leveraging the oral cavity to prevent unnecessary harm and reduce adverse events. By providing devices that optimize patient breathing and improve deployment speed, Surgicure aims to support medical professionals in delivering high-quality care and performing surgeries more effectively.
Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.
Jaia Robotics is a provider and developer of microsized autonomous and subsurface marine vehicles. It also provides comprehensive data collection services helping clients to affordable aquatic data collection. It also provides a multi-sensor configurable technology that requires minimal user training with wide-ranging capabilities compared to traditional crewed or uncrewed data collection systems.
Theromics Inc. is a biotechnology company focused on developing innovative cell therapies, particularly in the field of thermal ablation for cancer treatment. Founded in 2016 and based in West Bridgewater, Massachusetts, the company has created HeatSYNC Gel, a biopolymer thermal accelerant designed to enhance the effectiveness of microwave and radiofrequency ablation procedures. This gel improves the delivery and absorption of thermal energy in soft tissue and bone, optimizing the ablation zone's shape and volume. By increasing local tissue electrical conductivity, HeatSYNC Gel helps to prevent heat loss due to blood flow, allowing for more precise targeting of tumors and protecting surrounding healthy tissue. The gel can be administered through various methods, including syringe, laparoscope, and bronchoscope, and is intended to improve the overall efficacy of thermal ablation therapies while enabling personalized treatment approaches.
AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that will improve clinical practice and help reduce patient mortality.
Lenoss Medical specializes in developing innovative surgical and medical instruments aimed at treating spinal fractures. The company offers the osteopearl VBA system, a minimally invasive and cement-free technology that facilitates the natural healing process of bone. This approach is particularly beneficial for osteoporotic patients, as it leverages the body's inherent healing capabilities while minimizing the risk of complications associated with traditional treatments. By focusing on these advanced solutions, Lenoss Medical aims to improve patient outcomes and enhance the overall treatment landscape for spinal injuries.
First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.
Spiro is a proactive relationship management platform that creates contacts, organizes, and prioritizes opportunities. It provides managers with intelligent sales reports that help turn their sales team into a sales machine. The company was founded in 2014 and headquartered in Boston, Massachusetts.
RevBio is focused on developing innovative bone repair technology through its flagship product, Tetranite, which is an injectable, self-setting, osteoconductive bone adhesive biomaterial. This synthetic adhesive is designed to bond bone to bone and bone to metal in wet environments and is currently under FDA review for various applications in oral, craniofacial, orthopedic, and neurosurgical fields. Tetranite biodegrades over time, being replaced by new bone as part of the natural bone remodeling process, and serves as a scaffold to facilitate bone growth. By reducing the duration and complexity of medical procedures, RevBio's technology enables more minimally invasive surgeries and aims to improve patient outcomes by decreasing recovery time, pain, and overall costs associated with care. The company is building a diverse portfolio of applications within both dental and orthopedic markets.
At Orange Photonics, they are building products and services that drive toward a reliable, efficient and professional commerce infrastructure for the marijuana industry. Their initial product, LightLab, will set the bar for accurate, repeatable, cost-effective on-site marijuana potency testing. The services we will build around LightLab will collect and deliver data to aid decision makers in this market. Their customers want to make better data-based decisions in order to grow and optimize their business.
Pykus Therapeutics, Inc. is a medical technology company based in Boston, Massachusetts, founded in 2016 by ophthalmology residents. The company specializes in developing a dissolvable intraocular surgical device designed to enhance the experience of patients undergoing retinal surgery. Its innovative polymer-based hydrogel serves as a replacement for traditional intraocular gas, which can impose significant burdens on patients, such as the need for face-down positioning and prolonged periods of visual impairment. By utilizing this biodegradable hydrogel, Pykus Therapeutics aims to improve surgical outcomes and patient comfort, facilitating a faster and more comfortable recovery process after retinal procedures.
XCube R&D provides software infrastructure that automates testing and training process for machine learning algorithms. The company specializes in providing automation for OEMs and auto suppliers developing advanced driver assistance systems (ADAS) and autonomous vehicle programs. It offers StreamX Platform, a web-based interface to capture and store multi-sensor data, tag or annotate data based on the content important to the application, search data during the tagging and mining phase, launch an application, and save and automate a process. The company offers solutions in the areas of test and validation, training classifiers, real-time analysis, and automated regression testing. XCube R&D was founded in 2006 and is based in Nashua, New Hampshire.
Building Conversations specializes in augmented reality solutions designed for real estate developers and architecture firms. The company offers a mobile app that enhances communication among stakeholders by providing a platform for visualizing architectural concepts. This innovative tool is customizable and aims to streamline the building proposal process, addressing various challenges faced by users, whether they are involved in small neighborhood projects or large-scale developments. By facilitating clearer communication, Building Conversations enables designers to effectively convey their ideas, ultimately saving time and resources in the architectural design process.
Datarista, Inc. is a cloud-based platform that specializes in data-as-a-service, focusing on the delivery and integration of third-party sales and marketing data. Founded in 2015 and headquartered in Narragansett, Rhode Island, Datarista enables customers to seamlessly integrate their sales and marketing data into popular customer relationship management and marketing automation platforms. The platform offers both full and partial file installations, as well as standard and custom data sets tailored to the unique needs of each client, eliminating the need for extensive engineering resources from data providers. By enhancing data velocity and utility, Datarista serves as a service extension for data providers, allowing them to offer comprehensive solutions to their customers.
Xeno Biosciences Inc. is a biopharmaceutical company based in Somerville, Massachusetts, established in 2015. It specializes in developing innovative therapeutics aimed at addressing significant unmet needs in metabolic diseases, particularly obesity. The company's lead program, XEN-101, is an oral formulation that mimics the microbiome shift associated with Roux-en-Y Gastric Bypass (RYGB) surgery, promoting weight loss. Xeno Biosciences' approach involves a simple enteric-coated pill that delivers molecular oxygen to the lower gut, enabling a treatment strategy that replicates the effects of gastric bypass surgery on the gut microbiome.
Sialix Cancer Research provides cancer susceptibility antibodies and cancer-associated nucleoprotein antibodies for breast cancer. They also offer laser-based photodynamic endoscopic diagnosis using 5-aminolevulinic acid for early gastric adenocarcinoma and gastric adenoma.
Siamab Therapeutics is a biopharmaceutical company that focuses on developing therapies aimed at cancers characterized by the presence of abnormal carbohydrates, or glycans, on cancer cells. The company has created a technology platform that facilitates the discovery and development of anti-TACA therapeutic antibodies, which target tumor-associated carbohydrate antigens found in various solid tumors, including ovarian, prostate, pancreatic, gastric, and colon cancers. Founded in 2006 and based in Newton, Massachusetts, Siamab Therapeutics has licensed core technologies from the laboratory of glycobiology expert Ajit Varki. The company collaborates with a team of scientists and advisors specializing in oncology, glycoimmunology, and antibody engineering to advance its therapeutic programs.
Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.
MoFuse is a provider of a web-based platform designed to build and manage mobile websites. The company offers a monthly subscription service aimed at helping businesses deliver mobile media effectively. Its mobile content management system (CMS) allows users to enhance their mobile sites with features such as search functionality, mobile commerce, click-to-call options, mobile advertisements, and forms for capturing mobile data. MoFuse Premium also enables publishers to publish, promote, monetize, and analyze their mobile properties, facilitating a comprehensive approach to mobile content management for businesses.
iQuartic, Inc. develops cloud-based platforms aimed at enhancing data management within the healthcare industry. The company's technology facilitates electronic health record (EHR) and claims auditing, quality benchmarking, population health management, and risk profiling. Key offerings include the iQ EHR Network, which integrates disparate electronic medical record (EMR) systems; iQ EHR Auditing, which employs advanced analytics to identify inconsistencies in EHR and claims data; and iQ ACO Software, designed for accountable care organizations to gain insights into patient networks. Additional products include the EHR Data Auditor, which models patient behavior to identify under-reported cases, and the Diabetes Management Scorecard for assessing diabetes management across various EMRs. iQuartic also provides tools for chronic disease management, predicting hospital readmissions, and profiling clinicians. Established in 2012, the company operates from Boston, Massachusetts.
Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.
Pixability, Inc. is a Boston-based company that specializes in video advertising through its cloud-based software platform. This platform enhances YouTube campaigns by providing tools for insights on placements and keywords, channel management, and campaign optimization. Its flagship product, PixabilityONE, allows brands and agencies to run video campaigns across various platforms, including YouTube and connected TV services like Roku and Hulu. Pixability's technology is designed to ensure brand suitability and maximize the return on video ad spend, offering unique insights into campaign performance. The company is recognized as the only YouTube Measurement Partner certified for Brand Suitability and Contextual Targeting, collaborating with major measurement firms such as DoubleVerify and Nielsen. Pixability’s clientele includes media buyers, agencies, and brands across multiple sectors, reflecting its significant impact on the video advertising landscape since its establishment in 2008.
Copiun has set out to provide a PC backup and User Data Management solution that is less rather than more less for end users to do, less for IT administrators to do, and less expensive. This minimalistic approach has lead to a solution that while ideal for mid to large enterprises, is automated, secure, transparent to end users, and requires nearly zero IT administration, all at a cost that is nearly half the total cost of ownership when compared to traditional PC backup solutions.
SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.
Crimson Hexagon, Inc. is a provider of social media analysis software that enables businesses and organizations worldwide to gain insights from social data. Founded in 2007 and headquartered in Boston, Massachusetts, the company offers an AI-powered consumer insights platform that allows clients to analyze audiences, monitor brand perception, and assess campaign performance. Its technology provides access to a vast array of unstructured text and images from social and online public data sources, helping brands understand consumer sentiment and market trends. Crimson Hexagon serves a diverse clientele, including major companies such as Anheuser-Busch InBev, Adidas, and Starbucks. Additionally, the company supports nonprofit and educational organizations with reduced-fee access to its analytics platform. As of late 2018, Crimson Hexagon operates as a subsidiary of Runtime Collective Limited.
Tikatok is an on line community designed for children to write, illustrate and publish their own stories into real books. Tikatok was started by two moms that felt it is essential to give young children a place to channel their creativity and publish their work. For less than $20, children can self-publish their own paperback or hardcover book. With the help of "story sparks," a template-based system, children can easily start writing and illustrating stories. They can upload art directly to the site or mail it in. There are packages to schools and libraries for group orders. The site is very family centered, and has an awesome and well-thought-out privacy policy.
SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.
GateRocket, Inc. provides verification and debugging solutions for FPGAs. It offers RocketDrive, a device native verification system for complex FPGAs, which accelerates verification throughput and identifies problems with IP blocks, pin-outs, and tool chain anomalies. The company also provides RocketVision, a FPGA debug solution that automates test point insertion and detects differences between RTL and FPGA devices. The company was incorporated in 2003 and is headquartered in Bedford, Massachusetts.